Liposomal doxorubicin.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Journal of drug targeting (Print)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3109/10611869609015970PMID 8959485
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of the effect of liposome encapsulation on the vesicant properties, acute and cardiac toxicities, and antitumor efficacy of doxorubicin

  2004cited by this paper
• Studies on the myelosuppressive activity of doxorubicin entrapped in liposomes

  2004cited by this paper
• Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin

  2004cited by this paper
• Accumulation of doxorubicin and other lipophilic amines into large unilamellar vesicles in response to transmembrane pH gradients.

  1993cited by this paper
• Chromatographic analysis and pharmacokinetics of liposome-encapsulated doxorubicin in non-small-cell lung cancer patients.

  1993cited by this paper
• Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

  1993cited by this paper
• Initial clinical (phase I) trial of TLC D-99 (doxorubicin encapsulated in liposomes).

  1993cited by this paper
• In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release.

  1992cited by this paper
• Determination of transmembrane pH gradients and membrane potentials in liposomes.

  1992cited by this paper
• Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma.

  1992cited by this paper
• Kinetic analysis of tissue distribution of doxorubicin incorporated in liposomes in rats: I

  1992cited by this paper
• Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy.

  1991cited by this paper
• pH gradients and membrane transport in liposomal systems.

  1991cited by this paper
• Liposomes with entrapped doxorubicin exhibit extended blood residence times.

  1990cited by this paper
• Characterization of liposomal systems containing doxorubicin entrapped in response to pH gradients.

  1990cited by this paper
• Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study.

  1990cited by this paper
• Comparison of free and liposome encapsulated doxorubicin tumor drug uptake and antitumor efficacy in the SC115 murine mammary tumor.

  1990cited by this paper
• The accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey.

  1990cited by this paper
• A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.

  1990cited by this paper
• Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes

  1990cited by this paper
• Liposomes for the sustained drug release in vivo.

  1990cited by this paper
• Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin.

  1990cited by this paper
• Topoisomerase-targeting antitumor drugs.

  1989cited by this paper
• Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice.

  1989cited by this paper
• Proton electrochemical potential gradient in vesicles, organelles, and prokaryotic cells.

  1989cited by this paper
• Adriamycin-plasma membrane interaction in human erythrocytes.

  1988cited by this paper
• Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors.

  1988cited by this paper
• Large unilamellar liposomes with low uptake into the reticuloendothelial system

  1987cited by this paper
• Influence of lipid composition on the antitumor activity exerted by doxorubicin-containing liposomes in a rat solid tumor model.

  1987cited by this paper
• Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient.

  1986cited by this paper
• Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection.

  1985cited by this paper
• Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles.

  1985cited by this paper
• Superior therapeutic activity of liposome-associated adriamycin in a murine metastatic tumour model.

  1985cited by this paper
• In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes.

  1985cited by this paper
• Effect of liposome dose on the elimination of small unilamellar sphingomyelin/cholesterol vesicles from the circulation.

  1983cited by this paper
• Effects of liposome size on the degradation of bovine brain sphingomyelin/cholesterol liposomes in the mouse liver.

  1983cited by this paper
• Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes.

  1982cited by this paper
• Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice.

  1982cited by this paper
• Liposome disposition in vivo. III. Dose and vesicle-size effects.

  1981cited by this paper
• Liposomal protection of adriamycin-induced cardiotoxicity in mice.

  1980cited by this paper
• Cholesterol content of small unilamellar liposomes controls phospholipid loss to high density lipoproteins in the presence of serum

  1980cited by this paper
• In vitro and in vivo studies with adriamycin liposomes.

  1979cited by this paper
• Disintegration of phosphatidylcholine liposomes in plasma as a result of interaction with high-density lipoproteins.

  1978cited by this paper

• Fe3O4/SiO2 core-shell nanoparticles: dual-targeting drug carrier for doxorubicin delivery in cancer therapy

  2026cites this paper
• FAERS based disproportionality analysis and network pharmacology investigation of doxorubicin associated drug induced cardiotoxicity

  2025cites this paper
• Recent doxorubicin-conjugates in cancer drug delivery: Exploring conjugation strategies for enhanced efficacy and reduced toxicity.

  2025cites this paper
• Fabrication of Core‐Crosslinked Polymer Micelles via Photoinduced Azide Crosslinking

  2025cites this paper
• Cationic Azobenzene Tag to Enhance Liposomal Prodrug Retention and Tumor-Targeting Prodrug Activation for Improved Antitumor Efficacy.

  2025cites this paper
• Dynamic Dialysis Method for Characterizing Ammonia-Driven Drug Release from Liposomal Doxorubicin: Applicability and Kinetic Modeling.

  2025cites this paper
• The Use of Lipid-Based Nanocarriers to Improve Ovarian Cancer Treatment: An Overview of Recent Developments.

  2024cites this paper
• A Robust Chromatographic Method for Drug Release Profiling of Liposomal Doxorubicin HCl.

  2024cites this paper
• Remote loading in liposome: a review of current strategies and recent developments

  2024cites this paper
• Current knowledge of hybrid nanoplatforms composed of exosomes and organic/inorganic nanoparticles for disease treatment and cell/tissue imaging.

  2024cites this paper
• Emerging strategies for nanomedicine in autoimmunity.

  2024cites this paper
• Degradable and Biocompatible Magnesium Zinc Structures for Nanomedicine: Magnetically Actuated Liposome Microcarriers with Tunable Release

  2024cites this paper
• Comparative pharmacokinetics of free doxorubicin and a liposomal formulation in cats following intravenous administration

  2024cites this paper
• Understanding the Mechanical Properties of Ultradeformable Liposomes Using Molecular Dynamics Simulations

  2023cites this paper
• Exploring the Therapeutic Potential of Anticancer Heterocyclic Compounds: Role in Nanoscale Pharmacotherapy.

  2023cites this paper
• Development and DoE-ANN based optimization of novel swellable matrix-diffusible doxorubicin loaded zinc oxide nanoflowers using sonochemical-precipitation method.

  2023cites this paper
• Preparation of Doxorubicin Liposomes by Remote Loading Method.

  2023cites this paper
• PEG-conjugated bovine haemoglobin enhances efficiency of chemotherapeutic agent doxorubicin with alleviating DOX-induced splenocardiac toxicity in the breast cancer

  2023cites this paper
• Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research

  2023cites this paper
• Liposomes in Cancer Therapy: How Did We Start and Where Are We Now

  2023cites this paper
• Doxorubicin compositions with biocompatible terpolymer of N-vinylpyrrolidone, methacrylic acid and triethylene glycol dimethacrylate

  2023cites this paper
• Isolation, Purification, and Structural Characterization of Polysaccharides from Codonopsis pilosula and Their Anti-Tumor Bioactivity by Immunomodulation

  2023cites this paper
• Increased delivery and cytotoxicity of doxorubicin in HeLa cells using the synthetic cationic peptide pEM-2 functionalized liposomes.

  2023cites this paper
• DNA templated Click Chemistry via 5-vinyl-2'-deoxyuridine and an acridine-tetrazine conjugate induces DNA damage and apoptosis in cancer cells.

  2023cites this paper
• The multiple uses of azelaic acid in dermatology: mechanism of action, preparations, and potential therapeutic applications

  2023cites this paper
• Phytochemical-Based Nanomedicine for Targeting Tumor Microenvironment and Inhibiting Cancer Chemoresistance: Recent Advances and Pharmacological Insights.

  2023cites this paper
• Harnessing Ultrasound for Targeting Drug Delivery to the Brain and Breaching the Blood–Brain Tumour Barrier

  2022cites this paper
• Nanoaggregates of Biphilic Carboxyl-Containing Copolymers as Carriers for Ionically Bound Doxorubicin

  2022cites this paper
• Fusion of Tumor-Derived Exosomes with Long-Circulating and pH-Sensitive Liposomes Loaded with Doxorubicin for the Treatment of Breast Cancer

  2022cites this paper
• Rationale utilization of phospholipid excipients: a distinctive tool for progressing state of the art in research of emerging drug carriers

  2022cites this paper
• Extracorporeal Removal of Thermosensitive Liposomal Doxorubicin from Systemic Circulation after Tumor Delivery to Reduce Toxicities

  2022cites this paper
• PEGylated versus Non-PEGylated pH-Sensitive Liposomes: New Insights from a Comparative Antitumor Activity Study

  2022cites this paper
• Doxorubicin Intracellular Release Via External UV Irradiation of Dextran-g-poly(o-nitrobenzyl acrylate) Photosensitive Nanoparticles.

  2021cites this paper
• Cardiotoxicity in pediatric lymphoma survivors

  2021cites this paper
• Mechanisms and Insights for the Development of Heart Failure Associated with Cancer Therapy

  2021cites this paper
• From barriers to bridges; glycans in nonparenteral nanomedicines

  2021cites this paper
• EDTA-Gradient Loading of Doxorubicin into Ferrocene-Containing Liposomes: Effect of Lipid Composition and Visualization of Triggered Release by Cryo-TEM.

  2021cites this paper
• Safety Considerations of Cancer Nanomedicine-A Key Step toward Translation.

  2020cites this paper
• Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity

  2020cites this paper
• Drug Delivery Approaches for Doxorubicin in the Management of Cancers

  2020cites this paper
• Liposome-based codelivery of celecoxib and doxorubicin hydrochloride as a synergistic dual-drug delivery system for enhancing the anticancer effect

  2020cites this paper
• Three-Electrode 30–60 μL Mini-Cell for Ecologically Conscious Analytical Voltammetry with Common Macro- and Microelectrodes

  2020cites this paper
• Alginate microbeads with internal microvoids for the sustained release of drugs.

  2020cites this paper
• Histological evidence for the cardiac safety of high-dose pegylated liposomal doxorubicin in a patient with HIV-associated Kaposi sarcoma: a case report and literature review

  2019cites this paper
• Improved pharmacokinetics and reduced side effects of doxorubicin therapy by liposomal co-encapsulation with curcumin

  2019cites this paper
• Physicochemical characterization of dual action liposomal formulations: anticancer and antimicrobial

  2019cites this paper
• Topical delivery of TRPsiRNA-loaded solid lipid nanoparticles confer reduced pain sensation via TRPV1 silencing, in rats

  2018cites this paper
• Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen

  2018cites this paper
• Thymoquinone loaded in nanostructured lipid carrier showed enhanced anticancer activity in 4T1 tumor-bearing mice.

  2018cites this paper
• Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review.

  2017cites this paper
• Advances in nano-delivery systems for doxorubicin: an updated insight

  2017cites this paper
• Late Cardiotoxicity: Issues for Childhood Cancer Survivors

  2016cites this paper
• Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients

  2016cites this paper
• Glucosamine-anchored doxorubicin-loaded targeted nano-niosomes: pharmacokinetic, toxicity and pharmacodynamic evaluation

  2016cites this paper
• Long-term cardiac function in breast cancer survivors after multimodal treatment

  2016cites this paper
• Enhanced tumor delivery and antitumor response of doxorubicin-loaded albumin nanoparticles formulated based on a Schiff base

  2016cites this paper
• Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.

  2016cites this paper
• pH sensitive coiled coils: a strategy for enhanced liposomal drug delivery.

  2016cites this paper
• DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy.

  2016cites this paper
• [Liposomal doxorubicin in patients with breast cancer and concomitant cardiovascular diseases - interdisciplinary expert opinion].

  2016cites this paper
• Nonpegylated Liposomal Doxorubicin as a Component of R-CHOP Is an Effective and Safe Alternative to Conventional Doxorubicin in the Treatment of Patients With Diffuse Large B-Cell Lymphoma and Preexisting Cardiac Diseases.

  2015cites this paper
• Galactose engineered solid lipid nanoparticles for targeted delivery of doxorubicin.

  2015cites this paper
• Biochemical characterization of the interactions between doxorubicin and lipidic GM1 micelles with or without paclitaxel loading

  2015cites this paper
• Liposome armed with herpes virus-derived gH625 peptide to overcome doxorubicin resistance in lung adenocarcinoma cell lines

  2015cites this paper
• Quantitative and qualitative effect of gH625 on the nanoliposome-mediated delivery of mitoxantrone anticancer drug to HeLa cells.

  2015cites this paper
• Efficacy of CPX‐351, (cytarabine:daunorubicin) liposome injection, against acute lymphoblastic leukemia (ALL) xenograft models of the Pediatric Preclinical Testing Program

  2015cites this paper
• Liposomes: A targeted drug delivery system- A review

  2015cites this paper
• Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.

  2015cites this paper
• Modulation of Induced Cytotoxicity of Doxorubicin by Using Apoferritin and Liposomal Cages

  2014cites this paper
• Spermidinium closo-dodecaborate-encapsulating liposomes as efficient boron delivery vehicles for neutron capture therapy.

  2014cites this paper
• An overview of doxorubicin formulations in cancer therapy.

  2014cites this paper
• Characterization of a doxorubicin liposome formulation by a novel in vitro release test methodology using column-switching high-performance liquid chromatography.

  2014cites this paper
• DEVELOPMENT OF A NEW TARGETED LIPOSOMAL DELIVERY SYSTEM OF DOXORUBICIN MODIFIED WITH LYMPHOMA CELL SPECIFIC

  2014cites this paper
• Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy:a multicenter phase III study.

  2014cites this paper
• Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)

  2014cites this paper
• Boron lipid-based liposomal boron delivery system for neutron capture therapy: recent development and future perspective.

  2013cites this paper
• Cell penetrating peptide amphiphile integrated liposomal systems for enhanced delivery of anticancer drugs to tumor cells.

  2013cites this paper
• Advances in drug delivery and medical imaging using colloidal lyotropic liquid crystalline dispersions.

  2013cites this paper
• Long-term Cardiovascular Toxicity in Children, Adolescents, and Young Adults Who Receive Cancer Therapy: Pathophysiology, Course, Monitoring, Management, Prevention, and Research Directions A Scientific Statement From the American Heart Association

  2013cites this paper
• Expand classical drug administration ways by emerging routes using dendrimer drug delivery systems: a concise overview.

  2013cites this paper
• Octreotide labeled aggregates containing platinum complexes as nanovectors for drug delivery

  2013cites this paper
• Development of high boron content liposomes and their promising antitumor effect for neutron capture therapy of cancers.

  2013cites this paper
• Rapid determination of the encapsulation efficiency of a liposome formulation using column-switching HPLC.

  2013cites this paper
• A comparison of changes to doxorubicin pharmacokinetics, antitumor activity, and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems.

  2012cites this paper
• Constrained and UV-activatable cell-penetrating peptides for intracellular delivery of liposomes.

  2012cites this paper
• Nanospheres Encapsulating Anti-Leishmanial Drugs for Their Specific Macrophage Targeting, Reduced Toxicity, and Deliberate Intracellular Release

  2012cites this paper
• Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent

  2012cites this paper
• Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity.

  2012cites this paper
• Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.

  2012cites this paper
• Lipid-peptide vesicle nanoscale hybrids for triggered drug release by mild hyperthermia in vitro and in vivo.

  2012cites this paper
• Development of nanocapsules bearing doxorubicin for macrophage targeting through the phosphatidylserine ligand: a system for intervention in visceral leishmaniasis.

  2012cites this paper
• IN-VITRO CYTOTOXICITY ANALYSIS OF TAMOXIFEN CITRATE LOADED CROSS-LINKED GUAR GUM NANOPARTICLES ON JURKAT (HUMAN T-CELL LEUKEMIA) CELL LINE

  2012cites this paper
• Monoclonal Antibody and Liposomal Nanoparticle-based Targeting Therapies for Chronic Lymphocytic Leukemia

  2012cites this paper
• Peptide PHSCNK as an integrin α5β1 antagonist targets stealth liposomes to integrin-overexpressing melanoma.

  2012cites this paper
• N-cholesteryl sphingomyelin-A synthetic sphingolipid with unique membrane properties.

  2011cites this paper
• Neutral Liposomes and DNA Transfection

  2011cites this paper
• Anti-tumor efficacy of polymer-platinum(II) complex micelles fabricated from folate conjugated PEG-graft-α,β-poly [(N-amino acidyl)-aspartamide] and cis-dichlorodiammine platinum(II) in tumor-bearing mice.

  2011cites this paper
• Evaluation of selected antitumor agents as subversive substrate and potential inhibitor of trypanothione reductase: an alternative approach for chemotherapy of Leishmaniasis

  2011cites this paper
• Target‐Selective Drug Delivery through Liposomes Labeled with Oligobranched Neurotensin Peptides

  2011cites this paper
• Clickable functionalization of liposomes with the gH625 peptide from Herpes simplex virus type I for intracellular drug delivery.

  2011cites this paper